831 related articles for article (PubMed ID: 30885723)
21. MFAP2 Promotes the Proliferation of Cancer Cells and Is Associated With a Poor Prognosis in Hepatocellular Carcinoma.
Zhu X; Cheng Y; Wu F; Sun H; Zheng W; Jiang W; Shi J; Ma S; Cao H
Technol Cancer Res Treat; 2020; 19():1533033820977524. PubMed ID: 33280519
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value and oncogene function of heterogeneous nuclear ribonucleoprotein A1 overexpression in HBV-related hepatocellular carcinoma.
Ke RS; Zhang K; Lv LZ; Dong YP; Pan F; Yang F; Cai QC; Jiang Y
Int J Biol Macromol; 2019 May; 129():140-151. PubMed ID: 30731163
[TBL] [Abstract][Full Text] [Related]
23. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
24. Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma.
Hu B; Yang XB; Sang XT
Cancer Med; 2020 Oct; 9(20):7646-7662. PubMed ID: 32813933
[TBL] [Abstract][Full Text] [Related]
25. Identification of a five-immune gene model as an independent prognostic factor in hepatocellular carcinoma.
Chen H; Li Y; Xiao SY; Guo J
BMC Cancer; 2021 Mar; 21(1):278. PubMed ID: 33726698
[TBL] [Abstract][Full Text] [Related]
26. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
Front Immunol; 2020; 11():590618. PubMed ID: 33391264
[TBL] [Abstract][Full Text] [Related]
27. Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma.
Wen DG; Zhao XP; You Y; Liu ZJ
Cancer Immunol Immunother; 2021 Mar; 70(3):773-786. PubMed ID: 32989553
[TBL] [Abstract][Full Text] [Related]
28. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.
Woo HG; Wang XW; Budhu A; Kim YH; Kwon SM; Tang ZY; Sun Z; Harris CC; Thorgeirsson SS
Gastroenterology; 2011 Mar; 140(3):1063-70. PubMed ID: 21094160
[TBL] [Abstract][Full Text] [Related]
29. Establishment and validation of an immune infiltration predictive model for ovarian cancer.
Song Z; Zhang J; Sun Y; Jiang Z; Liu X
BMC Med Genomics; 2023 Sep; 16(1):227. PubMed ID: 37759229
[TBL] [Abstract][Full Text] [Related]
30. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size.
Wang Q; Luan W; Warren L; Fiel MI; Blank S; Kadri H; Mandeli J; Hiotis SP
J Immunother; 2016 Jan; 39(1):36-44. PubMed ID: 26641260
[TBL] [Abstract][Full Text] [Related]
33. Identification and development of TP53 mutation-associated Long non-coding RNAs signature for optimized prognosis assessment and treatment selection in hepatocellular carcinoma.
Chu C; Liu D; Wang D; Hu S; Zhang Y
Int J Immunopathol Pharmacol; 2023; 37():3946320231211795. PubMed ID: 37942552
[TBL] [Abstract][Full Text] [Related]
34. Genome-Wide Analysis of Prognostic lncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Hepatocellular Carcinoma.
Lin P; Wen DY; Li Q; He Y; Yang H; Chen G
Cell Physiol Biochem; 2018; 48(5):1953-1967. PubMed ID: 30092571
[TBL] [Abstract][Full Text] [Related]
35. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
Li W; Wu H; Xu X; Zhang Y
Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349
[TBL] [Abstract][Full Text] [Related]
37. MRGBP is a potential novel prognostic biomarker and is correlated with immune infiltrates in hepatocellular carcinoma.
Huang J; Chen X; Zhu W
Medicine (Baltimore); 2021 Mar; 100(12):e25234. PubMed ID: 33761715
[TBL] [Abstract][Full Text] [Related]
38. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
39. Construction and validation of a TP53-associated immune prognostic model for gastric cancer.
Nie K; Zheng Z; Wen Y; Shi L; Xu S; Wang X; Zhou Y; Fu B; Li X; Deng Z; Pan J; Jiang X; Jiang K; Yan Y; Zhuang K; Huang W; Liu F; Li P
Genomics; 2020 Nov; 112(6):4788-4795. PubMed ID: 32858135
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis.
Jin B; Gong Z; Yang N; Huang Z; Zeng S; Chen H; Hu S; Pan G
Tumour Biol; 2016 May; 37(5):5911-7. PubMed ID: 26592251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
